Compare DNUT & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNUT | ALLO |
|---|---|---|
| Founded | 1937 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.5M | 539.4M |
| IPO Year | 2021 | 2018 |
| Metric | DNUT | ALLO |
|---|---|---|
| Price | $3.67 | $2.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | $4.15 | ★ $8.35 |
| AVG Volume (30 Days) | 1.9M | ★ 14.4M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,522,616,000.00 | N/A |
| Revenue This Year | $0.55 | N/A |
| Revenue Next Year | $3.59 | $142,416.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.58 | $0.86 |
| 52 Week High | $5.73 | $4.46 |
| Indicator | DNUT | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 50.05 |
| Support Level | $3.09 | $2.14 |
| Resistance Level | $3.87 | $2.71 |
| Average True Range (ATR) | 0.24 | 0.15 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 13.61 | 50.00 |
Krispy Kreme Inc is a sweet-treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations world-wide. It derives maximum revenue from the U.S. segment.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.